52 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 THERMO FISHER 24/7 BIOPHARMA had the opportunity to catch up with Anil Kane, Executive Director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, at DCAT Week 2025. In our conversation, Kane spoke at length on the launch of Accelerator™ Drug Development, as well as Thermo Fisher’s approach to various ongoing bio/pharma trends. Accelerator™ Drug Development Thermo Fisher unveiled Accelerator™ Drug Development1 in October 2024, a “360-degree” CDMO and CRO services suite designed to offer comprehensive and customizable development capabilities. The program integrates the services of two companies previously acquired by Thermo Fisher: PPD, a CRO acquired for $17.4 billion2 in 2021, and Patheon, a CDMO acquired for approximately $7.2 billion3 in 2017. “Accelerator™ Drug Development offers CDMO and CRO services as one single vendor that covers end-to-end solutions for drug development,” says Kane. “Whether it’s a small molecule. biologics. mRNA, or even a cell or gene therapy, we can then convert these drug substances into drug product and support clinical packaging, labeling, and distribution, as well as clinical trials which will confirm the efficacy of these molecules — bringing these medications to patients faster.” Per Kane, Thermo Fisher could not offer the clinical research services part of the package before the company acquired PPD. Uniting these services with offerings at every stage of the clinical development journey under Accelerator™ Drug Development, the company has formalized their approach to assist in all phases of clinical trials, as well as the approvals process for regulatory agencies throughout the world. “From a drug substance perspective, we have a global network,” says Kane. “It’s the same with drug product development and manufacturing, as well as clinical trial depots and clinical packaging distribution capabilities. Across the board, we can support various regions for various markets. Wherever our partners choose to conduct clinical trials or launch their products based on the indications [and] market demand, we are here to support.” Navigating shifting seas Every pharma conference has its central point of discourse — those who attended the (then
RkJQdWJsaXNoZXIy MjY2OTA4MA==